Insider Selling: Personalis (NASDAQ:PSNL) CEO Sells $1,315,000.00 in Stock

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 100,000 shares of the firm’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $13.15, for a total transaction of $1,315,000.00. Following the completion of the transaction, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at approximately $3,103,215.90. The trade was a 29.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Trading Up 3.4%

Shares of PSNL traded up $0.43 during mid-day trading on Friday, reaching $13.02. 8,354,545 shares of the stock traded hands, compared to its average volume of 3,223,766. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -12.76 and a beta of 2.28. Personalis, Inc. has a 1 year low of $3.84 and a 1 year high of $13.37. The firm has a fifty day moving average price of $8.42 and a 200 day moving average price of $8.29.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The business had revenue of $15.47 million during the quarter, compared to analysts’ expectations of $14.48 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. On average, sell-side analysts anticipate that Personalis, Inc. will post -1.06 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on PSNL. BTIG Research lowered their target price on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Needham & Company LLC boosted their price target on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Morgan Stanley dropped their price objective on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Finally, Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Personalis has an average rating of “Moderate Buy” and an average target price of $11.00.

Institutional Trading of Personalis

Hedge funds have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. boosted its stake in Personalis by 273.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock worth $85,812,000 after buying an additional 7,896,714 shares in the last quarter. ARK Investment Management LLC grew its stake in shares of Personalis by 11.3% during the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after buying an additional 802,268 shares during the last quarter. Aberdeen Group plc increased its holdings in shares of Personalis by 36.1% in the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after buying an additional 861,948 shares during the period. Kennedy Capital Management LLC lifted its stake in shares of Personalis by 196.2% in the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after acquiring an additional 1,281,695 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Personalis by 1,332.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock valued at $11,531,000 after acquiring an additional 1,347,439 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.